Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV)

Quality of Life Research

Volumn 6, Issue 6, 1997, Pages 481-493

  Wu, A W ^a,b,d   Revicki, D A ^c   Jacobson, D ^a   Malitz, F E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d Health Services Research and Development Center   (United States)

Author keywords

HIV; MOS HIV; Reliability; Validity

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTATION; CONFERENCE PAPER; ETHNIC GROUP; HEALTH SURVEY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL HEALTH; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SOCIOECONOMICS;

FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; MALE; MINORITY GROUPS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS;

EID: 0030847865     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018451930750     Document Type: Conference Paper

References (75)

1. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724-735.
2. Stewart AL, Ware JE, eds. Measuring functioning and Well-being. The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.
3. Wu AW, Rubin HR, Mathews WC et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29: 786-798.
4. Manning WG, Newhouse JP, Ware JE. The Status of Health in Demand Estimation. Beyond Excellent, Good, Fair and Poor, 1991. Santa Monica, CA: The RAND Corporation, 1991.
5. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care, 1992; 30: 473-483.
6. O'Neill WM, Sherrard JS. Pain in human immunodeficiency virus disease: a review. Pain 1993; 54: 3-14.
7. Feinberg J, Cooper D, Hurwitz S. for the ACTG 204/Glaxo. Phase III international study of valaciclovir (vacv) for cytomegalovirus (cmv) prophylaxis in patients with advanced HIV disease. In: XI International Conference on AIDS. Vancouver, 7-12 July 1996.
8. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical health and mental health summary scores from the MOS HIV Health Survey. Med Care, in press.
9. Burgess A, Dayer M, Catalan J, Hawkins K, Gazzard B. The reliability and validity of two HIV-specific health related quality of life measures: a preliminary analysis. AIDS 1993; 7: 1001-1008.
10. Wu AW, Lichter SL, Richardson W et al. Quality of life in patients receiving clarithromycin for mycobacterium avium complex infection and AIDS. In: VIII International Conference on AIDS/III STD World Congress, Amsterdam, 19-24 July 1992.
11. Scott-Lennox J, McLaughlin Miley CJ, Mauskopf JA. Impact of lamivudine and zidovudine therapy on quality of life (QOL). In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
12. Wu AW, Jacobson D, Grant D, Scott-Lennox J. Quality of life scores predict clinical trial attrition and mortality. Abstracts of 4th Conf on Retroviruses Opportun Infect 1997; 31: 298.
13. Revicki DA, Wu AW, Brown R. Change in clinical status, health status and health utility outcomes in HIV-infected patients. Med Care 1995; 33(4): AS173-AS182.
14. Revicki DA, Swartz C. Quality of life outcomes of saquinavir, zalcitabine, and combination saquinavir-zalcitabine therapy for advanced HIV-infection. Abstracts 4th Conf Retroviruses Opportun Infect 1997; 27: 266.
15. Nunnally JC. Psychometric Theory, 2nd ed. New York: McGraw-Hill, 1978.
16. Singer J, Thorne A, Raboud J, Shafran S for the Canadian HIV Trials Network Protocol 010 Study Group. Estimating the effect of treatment on quality of life in the presence of missing data due to dropout and death. In press.
17. Scott-Lennox JA, Boyer JG, Ware JE, Wu AW. A psychometric validation of French, German, Italian, Dutch, and UK English translations of the MOS-HIV health status questionnaire. In press.
18. Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1996; 124(9): 792-802.
19. Wu AW, Gray S, Brookmeyer R, Safrin S. Quality of life in a double-blind randomized trial of 3 oral regimens for mild-to-moderate Pneumocystis carinii pneumonia in AIDS (ACTG108). In: XIth International Conference on AIDS, Vancouver, 7-12 July 1996.
20. The SOCA Research Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996; 114.
21. Wu AW, Jacobson D, Berzon R et al. The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Qual Life Res 1997; 6:1.
22. Zander KJ, Palitzsch M, Kirchberger I et al. HIV-infektion und gesundheitsbezogene Lebensqualität: psychometrische prüfung der deutschsprachigen version de "MOS-HIV"-fragebogens zur therapieerfolgskontrolle. (HIV infection and health related quality of life: psychometric testing of the German version of the MOS-HIV questionnaire.) AIDS-Forschung (AIFO) 1994; 9: 241-249.
23. Wu AW, Jacobson D, Clark B, Brookmyer R, Feinberg J. Quality of life associated with valacyclovir vs. high and low dose acyclovir for prophylaxis against cytomegalovirus in AIDS. Abstracts 4th Conf Retroviruses Opportun Infect 1997; 31: 297.
24. Rizzi M, Marchesi S, Morelli E, Avogadri M. Quality of Life in PWAS: Evaluation by the Medical Outcomes Study Instrument. AIOS Patient Care 1994; 8: 265-268.
25. Zander K, Jager H, Palitzsch M, Poppinger JV, Steinbuchel N, Bullinger M. Health related quality of life (HRQL) in HIV disease: influence of symptom load, functioning, mood and coping styles. In: IXth International Conference on AIDS, Berlin, June 1993.
26. Doob PR, MacFadden DK. The utility of health-related quality of life (HRQL) and energy-fatigue scales in evaluating response to therapy in clinical trials. In: IX International Conference on AIDS/HIV STD World Congress, Berlin, June 1993.
27. Copfer AE, Ampel NM, Hughes TE et al. The use of two measures of health-related quality of life in HIV-infected individuals: a cross-sectional comparison. Qual Life Res 1996; 5: 281-286.
28. Campbell A, Converse PE, Rodgers WL. The Quality of American Life: Perceptions, Evaluations and Satisfactions. New York: Russell Sage Foundation, 1976.
29. Ganz PA, Schag CA, Kahn B, Petersen L. Assessing the quality of life of HIV infected persons: clinical and descriptive information from studies with the HOPES. Psychol Health 1994; 9: 93-110.
30. Schag CA, Ganz PA, Kahn B, Petersen L. Assessing the needs and quality of life of patients with HIV infection: development of the HIV overview of Problems-Evaluation System (HOPES). Qual Life Res 1992; 1: 397-413.
31. Fanning MM, Emmott S, Sherett H, Renwick R, Freidland J. Validation of the Fanning Quality of Life Scale (FQLS) for HIV/AIDS. In: IXth International Conference on AIDS, Berlin, June 1993.
32. Nabulsi A, Revicki D, Conway D, Maurath C, Mills R, Leonard J. Quality of life consequences of adding ritonavir to current anti-viral therapy for advanced HIV patients. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
33. Wu AW, Jacobson D, Clark R et al. Validity of the EuroQol as a measure of health-related quality of life in an AIDS clinical trial. DIA Quality of Life Symposium, Charleston, SC, 12-13 May 1997.
34. Doob PR, Johnson KM, St Cyr J, MacFadden DK. Soft and hard measures of energy/fatigue in HIV Trials. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
35. Givertz F, Revicki DA. Discriminant validity of the medical outcomes study cognitive function scale in HIV disease patients. In: International Society of Quality of Life Research, Montreal, Quebec, 14-17 October 1995.
36. Wu AW, Coleson L, Holbrook J, Jabs DA. Measuring visual function and quality of life in CMV retinitis: development and preliminary validation of an instrument. Arch Ophthalmol 1996; 114: 841-847.
37. Volberding PA, Lagakos SW, Koch MA et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9.
38. Wu AW, Rubin HR, Bozzette SA et al: A longitudinal study of quality of life in asymptomatic HIV infection. In: Seventh International Conference on AIDS, Florence, July 1991.
39. Fischl MA, Richman DD, Hansen N et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727-37.
40. Wu AW, Rubin HR, Mathews WC et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early AIDS-related complex. J AIDS 1993; 6: 452-458.
41. Chaisson RE, Benson CA, Dube M et al. Clarithromycin for disseminated Mycobacterium avium-complex in AIDS patients. Ann Intern Med 1994; 121: 905-911.
42. Singer J, Thornel A, Khorasheh S, Raboud J, Wu AW, Shafran S for the CTN-010 Study Group. Eradication of bacteremia as a marker of symptom and health status improvement in AIDS patients with Mycobacterium avium complex bacteremia. In press.
43. Wu AW, Brookmeyer R, Gray S, Rubin HR, Safrin S. Responsiveness of a health status questionnaire in Pneumocystis carinii pneumonia. In: Second International Conference on Biopsychosocial Aspects of HIV Infection, Brighton, 7-10 July 1994.
44. Carretero MD, Burgess AP, Soler P, Soler M, Catalan J. Reliability and validity of an HIV-specific health related quality of life (QoL) measure for use with injecting drug users. AIDS 1996; 10: 1699-1705.
45. McDonnell K, Gielen A, Faden R, Wu AW, O'Campo P. Health-related quality of life among women living with HIV. National Conference on Women and HIV, Los Angeles, CA, 4-7 May, 1997.
46. Larrabee KD, Monga J, Eriksen N, Helfgott A. Quality of life assessment in pregnant women with the human immunodeficiency virus. Obstet Gynecol 1996; 88: 1016-1020.
47. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical tirai and nonclinical trials human immunodeficiency virus-infected cohorts. Med Care 1995; 33: AS15-AS25.
48. Ware JE, Keller SD, Gandek B, Brazier J, Sullivan M and the IQOLA Project Group. Evaluating translations of health status questionnaires: methods from the IQOLA Project. Int J Technol Assess Health Care, 1995; 11: 525-551.
49. Wu AW, Jacobson D, Clark B, Berzon R, Scott-Lennox J. Reliability, validity and responsiveness of the MOS-HIV HRQL instrument after cultural adaptation in Europe: results from an international clinical trial. In: Third Annual DIA Symposium on Quality of Life Evaluation. Boston, MA, 9-10 May 1996.
50. Hooker M, Newberry A, Nunn A. et al. Changes in quality of life (QOL) indices by treatment group for Delta trial participants beginning HIV therapy. In: XI International Conference on AIDS, Vancouver 7-12 July 1996.
51. Singer J, Thorne A, Raboud J et al. The Canadian randomized open label trial of combination therapy for MAC bacteremia: quality of life outcomes. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
52. Benson CA, Cohn DL, Williams P and the ACTG196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs rifabutin (RBT) vs CLA + RBY for the prevention of Mycobacterium avium complex (MAC) disease in HIV+ patients with CD4 counts ≤ 100 cells/μL. In: Proceedings of the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
53. Virgin G, Wolf E, Zander K et al. Efficacy of peptide T in the palliative treatment of neurological HIV-related symptoms. In: XI International Conference on AIDS, Vancouver 7-12 July 1996.
54. Cohen CJ, Duzube BJ, Day JM, Andradas V, Gagnon S, Rieker PP. The impact of pentoxifylline on quality of life. In: Tenth International Conference on AIDS, Yokohama, 1994.
55. Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 865-872.
56. Doob PR, MacFadden DK. Health-related quality of life (HRQL) as primary endpoint in pivotal clinical trials of Peptide T: practical and regulatory concerns. In: Symposium on Quality of Life Methodology and Quality of Life and HlV Infection: The Biopsychosocial Dimension, Amsterdam, July 1992.
57. MacFadden DK, Doob PR. Role of peptide T in palliation of HIV-1 related painful peripheral neuropathy. In: Seventh International Conference on AIDS, Florence, June 1991.
58. Wu AW, Clark R, Baigis J, Chase G. Sensitivity and responsiveness of the MOS-HIV Health Survey, Sickness Impact Profile (SIP) and Duke Activity Status Index (DASI) to peak oxygen consumption in persons with HIV disease. In: 4th Annual Conference of the International Society for Quality of Life Research, Vienna, 5-9 November 1997.
59. Hughes TE, Coons SJ, Kaplan RM, Draugalis R, Boyer JG. Comparison of the construct validity of the quality of well-being scale and the MOS-HIV-34 health survey in HIV-infected subjects. In: AHSR & FHSR 11th Annual Meeting, San Diego, June 1994.
60. Edwards AL, Hughes TE, Coons SJ, Dols CL, Ampel NM. Use of a health status questionnaire in HIV-infected patients at a Veterans Affairs Medical Center. In: Ninth International Conference on AIDS, Berlin: June 1993.
61. Kaplan R, Anderson JP, Patterson TL et al. Validity of the quality of well-being scale for persons with human immunodeficiency virus infection. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med 1995; 57(2): 138-147.
62. Banks L, Muurahainen N, Simons G et al. Physical functioning (pf), nutritional status, and phase angle (pa) in outpatients with HIV infection. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
63. Vedhara K, Nott KH. Psychosocial vulnerability to stress: a study of HIV-positive homosexual men. J Psychosom Res 1996; 41(3): 255-267.
64. Avila-Figueroa CR, Izazola-Licea JA, Hughef MD. Prospective changes in health-related quality of life in a cohort of HIV+ asymptomatic individuals. In: XI International Conference on AIDS, Vancouver, 7-12 July 1996.
65. Cohen M, Fischer L. The meanings of quality of life among health care providers and people living with HIV/AIDS and their relationship to treatment. In: XIth International Conference on AIDS, Vancouver, 7-12 July 1996.
66. Gerbaud L, Laurichesse H, Biolay S. et al. Health related quality of life among HIV patients - preliminary results of a prospective study. In: XIth International Conference on AIDS, Vancouver, 7-12 July 1996.
67. Goldstein M, Yancey T, Rogers DE. Self-rating of health in AIDS patients. In: 119th Annual Meeting of the American Public Health Association, Atlanta, November 1991.
68. Lynn LA, Silverman JJ, Forke CM. A comparison of HIV positive and HIV negative caregivers of patients with HIV infection. In: XIth International Conference on AIDS, Vancouver, 7-12 July 1996.
69. Petrak J, Henshaw P, Hedge B. The characteristics of individuals presenting with an AIDS defining illness coincident with their first positive HIV test results and the psychological sequelae of late presentation. In: XIth International Conference on AIDS, Vancouver, 7-12 July 1996.
70. Holmes WC, Shea JA. A new HIV disease-specific quality of life questionnaire: pilot data. Med Care In press.
71. Gosling S, Burgess A, Catalan P, Gazzard B. Quality of life: an individualized approach. In: IXth International Conference on AIDS, Berlin, June 1993.
72. Testa MA, Nackley JF. Methods for quality-of-life studies. Ann Rev Public Health 1994; 15: 535-559.
73. Wu AW, St Peter R, Cagney C. Health status assessment: completing the clinical database. J Gen Intern Med, 1997; 12: 254-255.
74. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3): S178-S189.
75. Holmes W, Bix B, Shea J. SF-20 score and item distribution in a human immunodeficiency virus-seropositive sample. Med Care 1996; 34: 562-569.